Close
Nordic 9Nordic 9

MRL Ventures (investor - Venture Capital)

United States mrlv.com
See something wrong or missing? Let us know
Offices:Cambridge

MRL Ventures is Merck’s independent early-stage therapeutics venture capital fund, an investment company operated from USA and backing early-stage, preclinical therapeutics companies to transform patient care.

Average round investment:66.99M USD
Average number per year:1.7
Distribution: 2024 (1)2023 (3)2022 (1)
Portfolio companies: Belgium ATB TherapeuticsUnited Kingdom EyeBiotechNetherlands VectorY Therapeutics See the entire list
Mostly invests in: United Kingdom United Kingdom (2) Health services (5)
See the entire list

Showing 3 of 5 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to MRL Ventures

Name Criteria
United States Redmile Group
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Belgium
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Switzerland Korify Capital
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
United States Cormorant Asset Management
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
United States venBio Partners
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Netherlands
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
United States Research Corporation Technologies
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
United Kingdom Abingworth
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Intuitive Ventures
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Alex Gorsky
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Driehaus Capital Management
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Belgium Merifin Capital
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top